Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, Antinori S
Department of Clinical Sciences, Section of Infectious Diseases and Immunopathology, University of Milan, L Sacco Hospital, Milan, Italy.
Int J STD AIDS. 2010 Nov;21(11):783-5. doi: 10.1258/ijsa.2010.010246.
Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce an increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case of severe rhabdomyolysis requiring hospitalization in an ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring a severe clinical occurrence of RAL-induced rhabdomyolysis from cases reported in literature are described.
雷特格韦（RAL）是一种HIV整合酶抑制剂，在初治和有抗逆转录病毒（ARV）治疗史的HIV阳性患者中，可能罕见地导致血清肌酸激酶（CK）升高。我们报告了1例有ARV治疗史的HIV/丙型肝炎合并感染患者，因使用含RAL的药物方案治疗而发生严重横纹肌溶解症并需住院治疗的病例。本文描述了与文献报道病例相比，更易导致RAL诱导的横纹肌溶解症出现严重临床症状的因素。
